Grant: Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
The University of British Columbia
$366,946.00
AAV Gene Therapy for the Treatment of Lipoprotein Lipase Deficiency
EF 2023-24 · 2024-03-14
Résumé
The project will lead to an improved and more cost-effective AAV-LPL gene therapy for the treatment of Lipoprotein Lipase (LPL) Deficiency. The previous limitations of the high costs of production of advanced biologics, such as Glybera, will be addressed through new cost-effective manufacturing in Canada. The project will develop a further optimized AAVbased gene therapy for the treatment of LPL Deficiency as a pilot demonstration of a cost-effective production strategy for new advanced gene therapeutics in Canada
Ministère
Programme
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Bénéficiaire
Emplacement
Vancouver|Vancouver, British Columbia, Canada
Type de bénéficiaire
Academia
Numéro d'entreprise
108161779
Type
Grant
Source
Proactive Disclosure - Grants and Contributions
Tel que publié
Agreement End Date
2025-03-01
Agreement Number
1014773
Agreement Start Date
2024-03-14
Agreement Title
AAV Gene Therapy for the Treatment of Lipoprotein Lipase Deficiency
Agreement Title (French)
Thérapie génique basée sur les virus adéno-associés (VAA) pour le traitement de la déficience en lipoprotéine lipase
Agreement Type
Grant
Agreement Value
$366,946.00
Amendment Number
0
Description
The project will lead to an improved and more cost-effective AAV-LPL gene therapy for the treatment of Lipoprotein Lipase (LPL) Deficiency. The previous limitations of the high costs of production of advanced biologics, such as Glybera, will be addressed through new cost-effective manufacturing in Canada. The project will develop a further optimized AAVbased gene therapy for the treatment of LPL Deficiency as a pilot demonstration of a cost-effective production strategy for new advanced gene therapeutics in Canada
Description (French)
Thérapie génique basée sur les virus adéno-associés (VAA) pour le traitement de la déficience en lipoprotéine lipase
Expected Results
In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.
Expected Results (French)
À court terme, les résultats prévus seront des collaborations renforcées entre l'industrie, le milieu universitaire et le gouvernement pour soutenir l'excellence en recherche. À moyen terme, les résultats attendus seront le développement de nouvelles technologies potentiellement perturbatrices avec des collaborateurs. À long terme, trouver des solutions collaboratives aux défis des politiques publiques et créer des systèmes d'innovation plus solides.
Federal Riding
Vancouver Quadra
Federal Riding (French)
Vancouver Quadra
Federal Riding Number
59039
NAICS Code
541710 - R&D in the physical, engineering and life sciences
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives
Program Name (French)
Programme de collaboration en science, en technologie et en innovation - Initiatives de collaboration en R-D
Program Purpose
Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.
Program Purpose (French)
Collaborer à des programmes multipartites de recherche-développement dans le but de profiter de la synergie entre la recherche transformatrice à haut risque et à haut rendement et le potentiel de découvertes scientifiques et de percées technologiques révolutionnaires dans des secteurs d’intervention prioritaires.
Recipient Business Number
108161779
Recipient City
Vancouver|Vancouver
Recipient Country
CA
Recipient Legal Name
The University of British Columbia
Recipient Postal Code
V6T 1Z3
Recipient Province or Territory
BC
Recipient Type
S
Reference Number
172-2023-2024-Q4-1014773
